KYMR.US Kymera Therapeutics Inc

Healthcare Biotechnology USA Stocks
127.57 USD
Close of Nov 15, 2026
62.91 142.92
Market cap
USD 10.9B
P/E
-
P/B
6.75x
ROE
-21.7%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is KYMR.US undervalued?

Graham number

The Graham number of Kymera Therapeutics Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Kymera Therapeutics Inc fundamental analysis

No fundamental analysis for Kymera Therapeutics Inc yet.

Kymera Therapeutics Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Kymera Therapeutics Inc

Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing KT-621, an oral STAT6 degrader in Phase 2b clinical trials for moderate to severe atopic dermatitis, asthma, COPD, EoE, CRSwNP, CSU, PN, BP, and others; KT-579, an oral IRF5 degrader in Phase 1 trials f…

Full company profile